Emerging Treatments for Childhood Interstitial Lung Disease

Area of Science:

• Pediatric Pulmonology
• Rare Diseases
• Interstitial Lung Disease

Background:

• Childhood interstitial lung disease (chILD) encompasses diverse disorders affecting lung parenchyma in children.
• Symptoms include dyspnea and hypoxemia, necessitating accurate diagnosis for prognosis and management.
• Many chILDs lack specific cures, with treatments often empirical.

Purpose of the Study:

• To summarize current therapeutic strategies for chILD.
• To explore potential future treatment options for pediatric interstitial lung disease.
• To address the high unmet need in chILD management.

Main Methods:

• Review of existing literature on chILD treatments.
• Analysis of outcomes from small clinical trials, including hydroxychloroquine and nintedanib.
• Discussion of current supportive and anti-inflammatory/immunosuppressive therapies.

Main Results:

• Current treatments for chILD are largely empirical, with limited randomized trial data.
• Hydroxychloroquine showed safety but modest efficacy; nintedanib demonstrated comparable safety and pharmacokinetics to adults in fibrotic chILD.
• Significant unmet needs persist in the effective treatment of chILD.

Conclusions:

• Effective treatments for many chILDs are lacking, emphasizing the need for further research.
• Novel therapeutic approaches are crucial to improve outcomes for children with interstitial lung disease.
• Continued investigation into targeted therapies is essential for advancing chILD care.